{"id":45065,"date":"2022-06-14T17:02:45","date_gmt":"2022-06-14T15:02:45","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-hpapis-and-cytotoxic-drugs-manufacturing-market-analysis-report-2022-2030-drug-origin-manufacturing-location-drug-type-type-of-pharmacological-molecule-application-researchandmarkets-com\/"},"modified":"2022-06-14T17:02:45","modified_gmt":"2022-06-14T15:02:45","slug":"global-hpapis-and-cytotoxic-drugs-manufacturing-market-analysis-report-2022-2030-drug-origin-manufacturing-location-drug-type-type-of-pharmacological-molecule-application-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-hpapis-and-cytotoxic-drugs-manufacturing-market-analysis-report-2022-2030-drug-origin-manufacturing-location-drug-type-type-of-pharmacological-molecule-application-researchandmarkets-com\/","title":{"rendered":"Global HPAPIs and Cytotoxic Drugs Manufacturing Market Analysis Report 2022-2030: Drug Origin, Manufacturing Location, Drug Type, Type of Pharmacological Molecule, Application – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “HPAPIs and Cytotoxic Drugs Manufacturing Market, by Drug Origin, by Manufacturing Location, by Drug Type, by Type of Pharmacological Molecule, by Application, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nHighly potent active pharmaceutical ingredients (HPAPIs) have an increasingly significant share of the pharmaceutical drug pipeline including anti-cancer treatments. Manufacturing highly potent APIs in large volumes requires extensive project experience with HPAPIs and a strong track record for audits and supply security.\n<\/p>\n

\nCytotoxic drugs are agents used to destroy cancer cells and tumors by inhibiting cell division. These drugs are widely used as anti-cancer agents and are used to boost the outcomes of surgery or radiotherapy, reduce metastasis, and diminish cancer symptoms.\n<\/p>\n

\nMarket Dynamics<\/strong>\n<\/p>\n

\nMarket players are engaged in inorganic activities, such as acquisitions, in order to expand its product portfolio, this is expected to drive the growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period.\n<\/p>\n

\nFor instance, in January 2019, Flamma Group, a life science company, acquired Teva’s Chemical Synthesis Center, the 40,000 sq. ft. cGMP facility in Malvern (U.S.). This laboratory and manufacturing site possesses a cGMP Pilot Plant with hydrogenation capabilities as well as wet-milling, 5 standard cGMP kilo lab suites, and 1 cGMP HPAPI kilo lab suite.\n<\/p>\n

\nKey players are focusing on receiving authorizations for their manufacturing facilities, from the regulatory authorities, and this is expected to drive the growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period. For instance, in December 2019, Cerbios-Pharma SA announced the authorization by Swissmedic of its cGMP bioconjugation suite for up-to commercial scale manufacturing of Antibody Drug Conjugates (ADCs).\n<\/p>\n

\nMoreover, in December 2019, Piramal Pharma Solutions, a division of Piramal Enterprises ltd., expanded its manufacturing facility in Riverview, Michigan, with an investment of approximately US$ 32 million to develop and manufacture potent and non-potent active pharmaceutical ingredients (APIs).\n<\/p>\n

\nKey features of the study:<\/strong>\n<\/p>\n